Latest Insider Transactions at Ra Medical Systems, Inc. (RMED)
This section provides a real-time view of insider transactions for Ra Medical Systems, Inc. (RMED). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ra Medical Systems, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ra Medical Systems, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
9,528
+2.81%
|
$0
$0.6 P/Share
|
|
Jan 22
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
9,528
+2.89%
|
$0
$0.43 P/Share
|
|
Jan 19
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
8,470
+2.65%
|
$0
$0.42 P/Share
|
|
Jan 18
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
8,470
+2.73%
|
$0
$0.41 P/Share
|
|
Jan 16
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
16,263
+2.73%
|
$0
$0.39 P/Share
|
|
Mar 23
2023
|
James Joseph Caruso |
BUY
Conversion of derivative security
|
Direct |
1,779
+50.0%
|
-
|
|
Mar 23
2023
|
Susanne Meline |
BUY
Conversion of derivative security
|
Indirect |
2,575
+50.0%
|
-
|
|
Mar 23
2023
|
David A Jenkins Executive Chairman and CEO |
BUY
Conversion of derivative security
|
Indirect |
711,967
+50.0%
|
-
|
|
Mar 23
2023
|
David A Jenkins Executive Chairman and CEO |
BUY
Conversion of derivative security
|
Direct |
277,597
+50.0%
|
-
|
|
Nov 20
2022
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-7.2%
|
$168
$2.67 P/Share
|
|
May 20
2022
|
Andrew C. Jackson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,361
-5.91%
|
$0
$0.3 P/Share
|
|
May 20
2022
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,241
-6.36%
|
$0
$0.3 P/Share
|
|
Nov 22
2021
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Open market or private sale
|
Direct |
8,149
-10.88%
|
$16,298
$2.62 P/Share
|
|
Nov 22
2021
|
Andrew C. Jackson CFO |
SELL
Open market or private sale
|
Direct |
2,684
-10.43%
|
$5,368
$2.62 P/Share
|
|
Nov 20
2021
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,752
-31.7%
|
-
|
|
Nov 20
2021
|
Andrew C. Jackson CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,759
-31.37%
|
-
|
|
Jun 04
2021
|
Martin J Colombatto |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+11.96%
|
-
|
|
Jun 04
2021
|
William R Enquist Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+17.57%
|
-
|
|
Jun 04
2021
|
Richard Mejia Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.42%
|
-
|
|
Jun 04
2021
|
Joan Stafslien Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+32.23%
|
-
|
|
Jun 04
2021
|
Susanne Meline |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+28.97%
|
-
|
|
May 20
2021
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.2%
|
$648
$3.15 P/Share
|
|
Feb 03
2021
|
Susanne Meline |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+40.78%
|
-
|
|
Jan 05
2021
|
Martin J Colombatto |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.22%
|
-
|
|
Jan 05
2021
|
Mark E Saad Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,227
+37.43%
|
-
|
|
Jan 05
2021
|
Richard Mejia Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,423
+34.43%
|
-
|
|
Jan 05
2021
|
William R Enquist Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,243
+32.91%
|
-
|
|
Nov 20
2020
|
Daniel Horwood General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
200
+0.91%
|
$1,000
$5.43 P/Share
|
|
Nov 20
2020
|
Andrew C. Jackson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
200
+0.53%
|
$1,000
$5.43 P/Share
|
|
Nov 20
2020
|
Jeffrey J Kraws Co-President |
BUY
Grant, award, or other acquisition
|
Direct |
200
+3.49%
|
$1,000
$5.43 P/Share
|
|
Nov 20
2020
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.2%
|
$1,296
$6.39 P/Share
|
|
Nov 19
2020
|
Richard Mejia Jr Director |
BUY
Open market or private purchase
|
Direct |
1,000
+10.5%
|
$5,000
$5.82 P/Share
|
|
Nov 19
2020
|
William R Enquist Director |
BUY
Open market or private purchase
|
Indirect |
5,263
+50.0%
|
$26,315
$5.82 P/Share
|
|
Nov 19
2020
|
Martin J Colombatto |
BUY
Open market or private purchase
|
Direct |
8,700
+36.04%
|
$43,500
$5.78 P/Share
|
|
Nov 19
2020
|
Joan Stafslien Director |
BUY
Open market or private purchase
|
Indirect |
4,410
+50.0%
|
$22,050
$5.67 P/Share
|
|
Nov 17
2020
|
Daniel Horwood General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
19,591
+47.45%
|
-
|
|
Nov 17
2020
|
Andrew C. Jackson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,276
+48.62%
|
-
|
|
Nov 17
2020
|
Jonathan Will Mc Guire CEO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
104,254
+48.65%
|
-
|
|
Oct 12
2020
|
William R Enquist Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.71%
|
-
|
|
Oct 12
2020
|
Richard Mejia Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.71%
|
-
|
|
Oct 12
2020
|
Martin J Colombatto |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+37.25%
|
-
|
|
Oct 12
2020
|
Mark E Saad Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+42.0%
|
-
|
|
Oct 12
2020
|
Joan Stafslien Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+44.44%
|
-
|